Ocugen and Celairis Therapeutics Enter into Exclusive License Agreement for OCU400 in Australia, New Zealand, and ASEAN
Key Highlights
- ➤OCU400 licensed exclusively to Celairis across Australia, New Zealand, and ASEAN markets
- ➤Ocugen may receive up to $7.1 million in development and milestone payments
- ➤$6.1 million tied to upfront payment and OCU400 top-line results expected Q1 2027
- ➤Ocugen receives high single-digit royalties and 50% of regional gross profits
- ➤Celairis assumes regional regulatory submissions, market access, and commercialization responsibilities
Expert Statements
Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen
“Australia, New Zealand, and ASEAN are large, diverse and complex markets, and establishing a partnership with a regional company like Celairis and its strong local network is critical to our goal of global patient access”
Shankar Musunuri, Chairman, Chief Executive Officer, and Co-Founder of Ocugen
“This agreement marks our third strategic regional partnership for OCU400, underscoring the growing momentum behind our global access strategy and bringing our potential one-time treatment gene therapy closer to patients around the world.”
Matt Zeller, Chief Executive Officer, Co-Founder, and Managing Director of Celairis
“Ocugen is the kind of partner Celairis was built for: a late-stage program, a clear strategy for reaching patients globally, and a conviction we share that geography should not decide access to new medicines.”
Matt Zeller, Chief Executive Officer, Co-Founder, and Managing Director of Celairis
“Celairis brings the development, regulatory, and market access capability to do that across our region, and we look forward to building the relationship with Ocugen.”
* Celairis receives exclusive rights to commercialize OCU400, Ocugen's investigational modifier gene therapy for retinitis pigmentosa (RP), in Australia, New Zealand, and member states of the Association of Southeast Asian Nations (ASEAN) markets * Expands access to a potential one-time treatment gene therapy for RP across a region with an estimated 725 million people, following potential OCU400 approval in the U.S. * Ocugen receives an upfront license fee, potential development and milestone payments totaling up to $7.1 million, including $6.1 million associated with the upfront payment and OCU400 top-line results (expected in the first quarter of 2027), a high single-digit percentage royalty on net sales, and 50% of gross profits from OCU400 net sales across the region * Celairis will be responsible for regional regulatory submissions, market access, and commercialization of OCU400 across the region MALVERN, Pa. and SYDNEY, Nov. 10, 2026 (GLOBE NEWSWIRE) -- Ocugen, Inc. ("Ocugen" or the "Company") (NASDAQ: OCGN), a pioneering biotechnology leader in gene therapies for blindness diseases, and Celairis Therapeutics Holdings Pty Ltd. ("Celairis"), a Sydney-based in-licensing, development, and commercialization biopharmaceutical company focused on Australia, New Zealand, Taiwan, and ASEAN, today announced the execution of an exclusive license agreement (the "License Agreement") granting Celairis an exclusive license to commercialize OCU400, Ocugen's investigational modifier gene therapy for the treatment of RP, in Australia, New Zealand, and ASEAN markets (the "Territory").
Get started
Create a free account to read the full story.